Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.
Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E. Winquist E, et al. Among authors: reid gk. Invest New Drugs. 2006 Mar;24(2):159-67. doi: 10.1007/s10637-006-5938-1. Invest New Drugs. 2006. PMID: 16502349 Clinical Trial.
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.
Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Davis AJ, et al. Among authors: reid gk. Invest New Drugs. 2003 Feb;21(1):85-97. doi: 10.1023/a:1022976528441. Invest New Drugs. 2003. PMID: 12795533 Clinical Trial.
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. Klisovic RB, et al. Among authors: reid gk. Clin Cancer Res. 2008 Apr 15;14(8):2444-9. doi: 10.1158/1078-0432.CCR-07-1320. Clin Cancer Res. 2008. PMID: 18413836 Clinical Trial.
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R, Vidal L, Griffin M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV. Plummer R, et al. Among authors: reid gk. Clin Cancer Res. 2009 May 1;15(9):3177-83. doi: 10.1158/1078-0432.CCR-08-2859. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383817 Free article. Clinical Trial.
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH Jr, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Garcia-Manero G, et al. Blood. 2008 Aug 15;112(4):981-9. doi: 10.1182/blood-2007-10-115873. Epub 2008 May 21. Blood. 2008. PMID: 18495956 Free PMC article. Clinical Trial.
19 results